Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: Single-center experience

被引:76
|
作者
Morgera, S
Scholle, C
Voss, G
Haase, M
Vargas-Hein, O
Krausch, D
Melzer, C
Rosseau, S
Zuckermann-Becker, H
Neumayer, HH
机构
[1] Humboldt Univ, Charite, Dept Nephrol, D-1086 Berlin, Germany
[2] Humboldt Univ, Charite, Dept Anesthesiol, D-1086 Berlin, Germany
[3] Humboldt Univ, Charite, Dept Cardiol, D-1086 Berlin, Germany
[4] Humboldt Univ, Charite, Dept Infect Dis, D-1086 Berlin, Germany
[5] Humboldt Univ, Charite, Dept Surg, D-1086 Berlin, Germany
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 97卷 / 04期
关键词
citrate anticoagulation; continuous renal replacement therapy; metabolic complications;
D O I
10.1159/000079171
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Regional anticoagulation with trisodium citrate is an effective form of anticoagulation for continuous renal replacement therapy (CRRT) in patients at a high risk of bleeding. In a prospective, observational study we compared an established regional citrate anticoagulation protocol [Mehta R et al: Kidney Int 1990; 38: 976-981] versus a standard heparin anticoagulation protocol focusing on acid-base and electrolyte derangements as well as on cost effectiveness. Methods and Results: 209 patients were included in the study. In 37 patients, citrate was used as the sole anticoagulant, 87 patients received low-dose heparin plus citrate, and 85 patients received only heparin as anticoagulant. A customized dialysate solution was used for citrate-anticoagulated CRRT (no buffer, no calcium, reduced sodium concentration). Filter life was significantly higher during citrate anticoagulation compared to heparin anticoagulation (80.2 +/- 60 vs. 30.2 +/- 32 h; p < 0.001). No difference was found between citrate and citrate-heparin anticoagulation (p = 0.310). Metabolic alkalosis was observed in more than 50% of patients on citrate anticoagulation. Alkalosis developed within the first 72 h after initiating treatment and could be reversed in almost all cases by increasing the dialysate flow rate. Hypercalcemia was observed in 13 patients on citrate anticoagulation. Patients with impaired liver function were particularly at risk. Systemic hypocalcemia, hypernatremia, and anion gap acidosis were not observed. Citrate anticoagulation was well tolerated hemodynamically. A longer filter life during citrate anticoagulation translated into a significant cost reduction compared to standard heparin anticoagulation (p < 0.01). Conclusion: Regional anticoagulation with trisodium citrate in combination with a customized calcium-free dialysate is a safe and effective alternative to a heparin-based anticoagulation regimen. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C131 / C136
页数:6
相关论文
共 50 条
  • [1] A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD)
    Mitchell, A
    Daul, AE
    Beiderlinden, M
    Schäfers, RF
    Heemann, U
    Kribben, A
    Peters, J
    Philipp, T
    Wenzel, RR
    CLINICAL NEPHROLOGY, 2003, 59 (02) : 106 - 114
  • [2] Regional citrate anticoagulation in high-volume continuous venovenous hemodialysis
    R Kalb
    J Ammann
    T Slowinski
    S Morgera
    D Kindgen-Milles
    Critical Care, 15 (Suppl 1):
  • [3] Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation
    Meier-Kriesche, HU
    Gitomer, J
    Finkel, K
    DuBose, T
    CRITICAL CARE MEDICINE, 2001, 29 (04) : 748 - 752
  • [4] Regional citrate anticoagulation in continuous venovenous hemodiafiltration
    Kutsogiannis, DJ
    Mayers, I
    Chin, WDN
    Gibney, RTN
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (05) : 802 - 811
  • [5] Protocolized Regional Citrate Anticoagulation during Continuous Renal Replacement Therapy: A Single Center Experience
    Pachisia, Anant, V
    Kumar, Praveen G.
    Harne, Rahul
    Jagadeesh, K. N.
    Patel, Sweta J.
    Pal, Divya
    Tyagi, Pooja
    Pattajoshi, Swagat
    Brar, Keerti
    Patel, Parimal B.
    Zatakiya, Ronak
    Chandra, Subhash
    Govil, Deepak
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2024, 28 (09) : 859 - 865
  • [6] Regional citrate anticoagulation (RCA) for continuous venovenous hemodiafiltration (CVVHDF): initial experience
    M Durão
    JC Monte
    C Laselva
    VG Pereira
    BF Santos
    M Cendoroglo
    OFP Santos
    E Knobel
    Critical Care, 5 (Suppl 3):
  • [7] Continuous veno-venous hemofiltration with regional citrate anticoagulation: A four-year single-center experience
    Cassina, Tiziano
    Mauri, R.
    Engeler, A.
    Giannini, O.
    International Journal of Artificial Organs, 2008, 31 (11): : 937 - 943
  • [8] Continuous veno-venous hemofiltration with regional citrate anticoagulation: A four-year single-center experience
    Cassina, T.
    Mauri, R.
    Engeler, A.
    Giannin, O.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (11): : 937 - 943
  • [9] Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation
    Khadzhynov, Dmytro
    Schelter, Christin
    Lieker, Ina
    Mika, Alice
    Staeck, Oliver
    Neumayer, Hans. -H.
    Peters, Harm
    Slowinski, Torsten
    JOURNAL OF CRITICAL CARE, 2014, 29 (02) : 265 - 271
  • [10] Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge
    Luca Gabutti
    Claudio Marone
    Giuseppe Colucci
    Francesca Duchini
    Carlo Schönholzer
    Intensive Care Medicine, 2002, 28 : 1419 - 1425